Who we are

Find out more about the Unizima team

An outstanding team with a clear vision

Our multicultural team is made up of functional experts, scientists, engineers and clinicians who are there to support our clients from project inception to operational readiness.

Together, we have the experience and drive to radically innovate the supply of biologics.

Unizima is part of the Univercells Group – a campus of start-ups and scale-ups establishing a global ecosystem that will make biologics available to all.

Our Vision

Our vision is a world in which biologics are available to all to improve health and life everywhere.  

Our Mission

We are on a mission to provide access to the people, the skills, and the technology needed for local bioproduction – in a way that is integrated in and supports local health systems.

Leadership

CEO Unizima
Founder Unizima & CEO Univercells Group
CTO & Co-Founder, Chairman of the Board of Directors​

Team of Experts

Vanessa Daubront

Tech Transfer Lead

Barbara Cornelissen

Strategy Lead

David Honba

Head of Business Development

Olivier André

Business Partner In-Licensing

Benoît Grégoire

Fill Finish Lead

Board of Directors

History

1990
Belgian and Walloon ecosystem

Since the 90s, Wallonia has been a bio-manufacturing hub with the creation of several international companies.

2013
Launch of Univercells

In 2013, Univercells was created with the ambition to make biologics available and affordable to all.

2020
Unizima

In 2020, Univercells launches Unizima to design, build, maintain and operate a model to develop specialized care centers with dedicated bioproduction facilities, access to diagnostic infrastructure and best in-class care protocols.

1990
Belgian and Walloon ecosystem

Since the 90s, Wallonia has been a bio-manufacturing hub with the creation of several international companies.

2013
Launch of Univercells

In 2013, Univercells was created with the ambition to make biologics available and affordable to all.

2020
Unizima

In 2020, Univercells launches Unizima to design, build, maintain and operate a model to develop specialized care centers with dedicated bioproduction facilities, access to diagnostic infrastructure and best in-class care protocols.